Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 3/20 | 0.72 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.58 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6460048 | 0.84 | AHR (1.00) | AHRALOX5PTGS1PTGS2DAO | |
| SCHEMBL2132702 | 0.84 | AHR (1.00) | AHRALOX5PTGS1PTGS2DAO | |
| SCHEMBL2143573 | 0.84 | AHR (1.00) | AHRALOX5PTGS1PTGS2DAO | |
| SCHEMBL18143811 | 0.83 | AHR (0.80) | AHRALOX5PTGS1PTGS2NFE2L2 | |
| SCHEMBL21020531 | 0.83 | ALOX5 (0.56) | AHRALOX5PTGS1PTGS2MAOA | |
| SCHEMBL18143815 | 0.83 | AHR (0.80) | AHRALOX5PTGS1PTGS2NFE2L2 | |
| SCHEMBL26446176 | 0.83 | AHR (0.71) | AHRALOX5PTGS1PTGS2MAOA | |
| SCHEMBL9971885 | 0.80 | MAOA (0.60) | AHRALOX5PTGS1PTGS2MAOA | |
| SCHEMBL11529471 | 0.80 | MAOA (0.60) | AHRALOX5PTGS1PTGS2MAOA | |
| SCHEMBL22485553 | 0.80 | MAOA (0.60) | AHRALOX5PTGS1PTGS2MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212568-A1 | MICRORNA-MEDIATED METHODS FOR REJUVENATING CNS GLIAL POPULATIONS | UNIVERSITY OF ROCHESTER | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212568-A1 | MICRORNA-MEDIATED METHODS FOR REJUVENATING CNS GLIAL POPULATIONS | MYT1, STAT3, MYC | AHR 3980/4885ALOX5 4095/4885PTGS1 3084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.